REGENERON PHARMACEUTICALS, INC. (REGN)
Pharmaceutical Preparations · Pharmaceutical Preparations · NASDAQ
$810.24
+0.65%
Investingg Score
65.7 / 100
Hold
Business overview
- Operating margin stands at 24.9%.
- FCF margin is reported at 28.4%.
These margins reflect solid operational profitability and strong cash conversion efficiency.
Financial health
- Balance sheet pillar score is 89 out of 100.
- Risk pillar score reaches 100 out of 100.
These high scores indicate a very strong financial position with minimal structural balance sheet risk.
- Gross Margin
- Data unavailable
- Operating Margin
- 24.9%
- Current Ratio
- 4.1x
- Debt / Equity
- 0.06
- Free Cash Flow (TTM)
- $4.1B
- Interest Coverage
- Data unavailable
Valuation
- EV to EBITDA ratio is -0.25.
- PS ratio is recorded at 0.
- P/E ratio and FCF yield are data unavailable.
These valuation metrics present a mixed and limited picture due to missing data points.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 0.0x
- EV / EBITDA
- -0.3x
- FCF Yield
- Data unavailable
Key risks
- Data unavailable for specific structured risk factors in the provided dataset.
- Elevated RSI of 88.61 introduces technical pullback uncertainty.
- Low revenue growth YoY of 1% signals limited top-line expansion.
Market cap $0 · data as of 2026-08-18
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze REGN with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.